Advertisement

Breast Cancer Research and Treatment

, Volume 155, Issue 3, pp 613–613 | Cite as

Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option

  • Ziyan Yuan Pessetto
  • Ying Yan
  • Tadayoshi Bessho
  • Amarnath NatarajanEmail author
Erratum

Erratum to: Breast Cancer Res Treat (2012) 134:511–517 DOI 10.1007/s10549-012-2079-4

Figure 1c in the original publication had nuclear lamin B controls inserted in both the cytoplasm and nucleus sets. The revised Fig. 1c show the correct GAPDH controls. The authors regret this error.
Fig. 1

a Proposed hypothesis: Small molecule inhibitors of BRCT(BRCA1)–phosphoprotein interaction will increase the sensitivity of cancer cells to DNA damage based therapeutics. The inhibitor is represented as a red X. b Competitive inhibition curves for BRCT(BRCA1) inhibitor peptides 1 (Ac-pSPTF-CO2H) and 2 (Ac-R10 G-pSPTF-CO2H). c IP and IB studies with and without the BRCT inhibitor 2 in the presence and absence of IR-induced DNA damage

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Ziyan Yuan Pessetto
    • 1
  • Ying Yan
    • 1
  • Tadayoshi Bessho
    • 1
  • Amarnath Natarajan
    • 1
    • 2
    • 3
    Email author
  1. 1.Eppley Institute for Cancer ResearchUniversity of Nebraska Medical CenterOmahaUSA
  2. 2.Department of Pharmaceutical SciencesUniversity of Nebraska Medical CenterOmahaUSA
  3. 3.Department of Genetics Cell Biology and AnatomyUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations